SCHEMBL4748136

SCHEMBL4748136

NCCCCN(Cc1ccc(C(=O)NNc2ccccc2)cc1)Cc1ncc[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.42
PTGS2 P35354 2/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
GAA P10253 4/20 0.39
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
HDAC1 Q13547 5/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HTT P42858 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HDAC3 O15379 3/20 0.37
HDAC2 Q92769 3/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC8 Q9BY41 2/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890220 0.88 CXCR4 (0.42) CXCR4PTGS2SMN1; SMN2GAACYP2D6
SCHEMBL14005302 0.87 PTGS2 (0.50) PTGS2SMN1; SMN2GAAHDAC1KDM4E
SCHEMBL4748582 0.83 PTGS2 (0.51) PTGS2SMN1; SMN2GAAHDAC1KDM4E
SCHEMBL14004916 0.83 CXCR4 (0.42) CXCR4HDAC1KDM4EALDH1A1HDAC3
SCHEMBL1205255 0.79 CXCR4 (0.46) CXCR4
SCHEMBL4745161 0.75 PTGS2 (0.44) PTGS2SMN1; SMN2GAAHDAC1KDM4E
SCHEMBL4744997 0.74 ACHE (0.51) PTGS2SMN1; SMN2GAAHDAC1LMNA
SCHEMBL14005295 0.72 HDAC1 (0.46) PTGS2SMN1; SMN2GAAHDAC1LMNA
SCHEMBL13078665 0.72 CXCR4 (0.41) CXCR4
SCHEMBL1206780 0.71 MEP1B (0.50) CXCR4SMN1; SMN2GAACYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293711-A1 Chemokine receptor modulators METASTATIX, INC. 2008-11-27 US disclosed
US-20080293711-A1 Chemokine receptor modulators METASTATIX, INC. 2008-11-27 US disclosed
US-20080293711-A1 Chemokine receptor modulators METASTATIX, INC. 2008-11-27 US disclosed
WO-2008112156-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS (US) 2008-09-18 WO disclosed
WO-2008112156-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293711-A1 Chemokine receptor modulators CCR5, CCL2, CXCR4 CXCR4 3/4885PTGS2 604/4885SMN1; SMN2 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.